1262769-98-1

CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice^[1].
CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats^[1].
CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice^[1].